GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Avantor Inc (NYSE:AVTR) » Definitions » Debt-to-EBITDA

AVTR (Avantor) Debt-to-EBITDA : 1.39 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Avantor Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Avantor's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $821 Mil. Avantor's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $3,235 Mil. Avantor's annualized EBITDA for the quarter that ended in Dec. 2024 was $2,920 Mil. Avantor's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was 1.39.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Avantor's Debt-to-EBITDA or its related term are showing as below:

AVTR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -44.46   Med: 5.12   Max: 8.5
Current: 2.74

During the past 9 years, the highest Debt-to-EBITDA Ratio of Avantor was 8.50. The lowest was -44.46. And the median was 5.12.

AVTR's Debt-to-EBITDA is ranked worse than
68.22% of 428 companies
in the Medical Devices & Instruments industry
Industry Median: 1.395 vs AVTR: 2.74

Avantor Debt-to-EBITDA Historical Data

The historical data trend for Avantor's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avantor Debt-to-EBITDA Chart

Avantor Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only 6.40 5.20 4.13 5.04 2.74

Avantor Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.85 5.44 4.60 5.45 1.39

Competitive Comparison of Avantor's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Avantor's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avantor's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Avantor's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Avantor's Debt-to-EBITDA falls into.



Avantor Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Avantor's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(821.1 + 3234.7) / 1478.2
=2.74

Avantor's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(821.1 + 3234.7) / 2920
=1.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.


Avantor  (NYSE:AVTR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Avantor Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Avantor's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Avantor Business Description

Traded in Other Exchanges
Address
100 Matsonford Road, Suite 200, Building One, Radnor Corporate Center, Radnor, PA, USA, 19087
Avantor Inc provider of products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company has three geographic segments: the Americas, Europe, and AMEA. The company's product group consists of Equipment & instrumentation, Services & specialty procurement, Proprietary materials & consumables, and Third-party materials & consumables. Materials & consumables include high-purity chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, and education and microbiology and clinical trial kits, peristaltic pumps and fluid handling tips.
Executives
Steven W Eck officer: SVP & Chief Accounting Officer C/O CSS INDUSTRIES, INC., 450 PLYMOUTH ROAD, SUITE 300, PLYMOUTH MEETING PA 19462
Christophe Couturier officer: See Remarks 9 FOURTH AVENUE, C/O OVASCIENCE INC., CAMBRIDGE MA 02451
James Bramwell officer: EVP, Strategic Partners C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Benoit Gourdier officer: EVP, Biopharma Production 100 MATSONFORD ROAD, RADNOR PA 19087
Frederic Vanderhaegen officer: EVP, Europe C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Brittany Hankamer officer: EVP, Chief HR Officer 100 MATSONFORD ROAD, RADNOR PA 19087
R. Brent Jones officer: EVP, Chief Financial Officer C/O PALL CORPORATION, 25 HARBOR PARK DRIVE, PORT WASHINGTON NY 11050
Claudius Sokenu officer: EVP, Chief Legal & Compliance C/O UNISYS CORPORATION, 801 LAKEVIEW DRIVE, BLUE BELL PA 19422
Randy Lee Stone officer: EVP, Proprietary Products 974 CENTRE ROAD, CRP 730, WILMINGTON DE 19805
Gerard Brophy officer: EVP, Biopharma Production C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Kitty Sahin officer: EVP, Strategy&Corp Development 100 MATSONFORD ROAD, RADNOR PA 19087
Michael Stubblefield director, officer: President and CEO C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Thomas A Szlosek officer: EVP and CFO HONEYWELL INTERNATIONAL INC., 115 TABOR ROAD, MORRIS PLAINS NJ 07950
Rajiv Gupta director 234 RAVENCLIFF DRIVE, ST DAVIDS PA 19087
Joseph R Massaro director 5725 DELPHI DRIVE, TROY MI 48098